Cargando…

Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study

BACKGROUND: Tuberous sclerosis complex (TSC) is an autosomal dominant disease that affects multiple organs including the brain. TSC is strongly associated with broad neurodevelopmental disorders, including autism spectrum disorder symptomatology. Preclinical TSC studies have indicated altered neuron...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Andel, Dorinde M., Sprengers, Jan J., Oranje, Bob, Scheepers, Floortje E., Jansen, Floor E., Bruining, Hilgo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204231/ https://www.ncbi.nlm.nih.gov/pubmed/32381101 http://dx.doi.org/10.1186/s13229-020-00335-4

Ejemplares similares

Bumetanide Effects on Resting-State EEG in Tuberous Sclerosis Complex in Relation to Clinical Outcome: An Open-Label Study
por: Juarez-Martinez, Erika L., et al.
Publicado: (2022)

Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders: A Pilot Randomized Controlled Trial
por: van Andel, Dorinde M., et al.
Publicado: (2022)

Bumetanide As a Candidate Treatment for Behavioral Problems in Tuberous Sclerosis Complex
por: Vlaskamp, Chantal, et al.
Publicado: (2017)

The sensory-reactivity PROM set: identification of a parent reported outcome measure set for autism spectrum disorder
por: van Andel, Dorinde M., et al.
Publicado: (2021)

Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol
por: Geertjens, Lisa, et al.
Publicado: (2022)

Bumetanide for autism: Open‐label trial in six children
por: Fernell, Elisabeth, et al.
Publicado: (2021)

The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC)
por: Feliciano, David M.
Publicado: (2020)

Off-Label Use of Bumetanide for Brain Disorders: An Overview
por: Kharod, Shivani C., et al.
Publicado: (2019)

Serious Games as Potential Therapies: A Validation Study of a Neurofeedback Game
por: Coenen, Femke, et al.
Publicado: (2019)

Sensory modulation disorders in childhood epilepsy
por: van Campen, Jolien S., et al.
Publicado: (2015)

Measurement of excitation-inhibition ratio in autism spectrum disorder using critical brain dynamics
por: Bruining, Hilgo, et al.
Publicado: (2020)

Myelin Pathology Beyond White Matter in Tuberous Sclerosis Complex (TSC) Cortical Tubers
por: Mühlebner, Angelika, et al.
Publicado: (2020)

Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
por: Thiele, Elizabeth A., et al.
Publicado: (2021)

Experiences of Siblings of Children With Neurodevelopmental Disorders: Comparing Qualitative Analysis and Machine Learning to Study Narratives
por: Bastiaansen, Jort. A. J., et al.
Publicado: (2022)

The role of glia in epilepsy, intellectual disability, and other neurodevelopmental disorders in tuberous sclerosis complex
por: Wong, Michael
Publicado: (2019)

Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?
por: Moavero, Romina, et al.
Publicado: (2020)

Bumetanide: Metabolic alkalosis: case report
Publicado: (2021)

Novel Histopathological Patterns in Cortical Tubers of Epilepsy Surgery Patients with Tuberous Sclerosis Complex
por: Mühlebner, Angelika, et al.
Publicado: (2016)

Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex
por: Vergeer, Menno, et al.
Publicado: (2019)

The association of neurodevelopmental abnormalities, congenital heart and renal defects in a tuberous sclerosis complex patient cohort
por: Robinson, Jessica, et al.
Publicado: (2022)

A comparison of two studies and the prevalence and sex ratio of Neurodevelopmental conditions in Tuberous Sclerosis Complex
por: Runicles, Abigail K., et al.
Publicado: (2021)

Behavioral disinhibition and antiepileptic treatment in childhood epilepsy: A retrospective cohort study
por: van Tuijl, Diana C., et al.
Publicado: (2017)

Tuberous (or Tuberose) Sclerosis
por: Fowler, J. S., et al.
Publicado: (1910)

Modeling the quantitative nature of neurodevelopmental disorders using Collaborative Cross mice
por: Molenhuis, Remco T., et al.
Publicado: (2018)

The epileptogenic zone in children with tuberous sclerosis complex is characterized by prominent features of focal cortical dysplasia
por: Hulshof, Hanna M., et al.
Publicado: (2021)

Bumetanide Exposure Association with Alzheimer’s Disease Risk
por: Graber-Naidich, Anna, et al.
Publicado: (2023)

Tuberous sclerosis
por: George, Anisha, et al.
Publicado: (2015)

Shared mechanisms of neural circuit disruption in tuberous sclerosis across lifespan: Bridging neurodevelopmental and neurodegenerative pathology
por: Litwa, Karen
Publicado: (2022)

A single-center observational study on long-term neurodevelopmental outcomes in children with tuberous sclerosis complex
por: Mammadova, D., et al.
Publicado: (2023)

Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial
por: Kotulska, Katarzyna, et al.
Publicado: (2020)

Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment
por: Mills, James D., et al.
Publicado: (2017)

Following Excitation/Inhibition Ratio Homeostasis from Synapse to EEG in Monogenetic Neurodevelopmental Disorders
por: Geertjens, Lisa, et al.
Publicado: (2022)

A randomised controlled trial of bumetanide in the treatment of autism in children
por: Lemonnier, E, et al.
Publicado: (2012)

Bumetanide Prevents Brain Trauma-Induced Depressive-Like Behavior
por: Goubert, Emmanuelle, et al.
Publicado: (2019)

Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel
por: Kaila, Kai, et al.
Publicado: (2022)

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders
por: Franz, David N., et al.
Publicado: (2017)

Electro-clinical and neurodevelopmental outcome in six children with early diagnosis of tuberous sclerosis complex and role of the genetic background
por: Savini, M. N., et al.
Publicado: (2020)

Specific pattern of maturation and differentiation in the formation of cortical tubers in tuberous sclerosis omplex (TSC): evidence from layer-specific marker expression
por: Mühlebner, Angelika, et al.
Publicado: (2016)

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
por: Boyarko, Ben, et al.
Publicado: (2023)

AUTISM IN TUBEROUS SCLEROSIS
por: Khanna, Rakesh, et al.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_rof95ud387um3rubjss2c3l0r3